E-cigarette or vaping product use-associated lung injury (EVALI)

Abstract

E-cigarette or vaping product use-associated lung injury (EVALI), is an acute or subacute respiratory illness characterized by a spectrum of clinicopathologic findings mimicking various pulmonary diseases. According to the CDC (Centers for Disease Control and Prevention) criteria, EVALI is a clinical diagnosis that requires the use of an e-cigarette in the 90 days preceding the appearance of initial symptoms; pulmonary infiltrates on a plain chest radiograph or chest CT, and the absence of any other possible etiology, such as infection. In this article, we discuss electronic nicotine delivery systems as well as the etiology, clinical presentation, evaluation, treatment, and complications of EVALI.